<DOC>
	<DOCNO>NCT00730990</DOCNO>
	<brief_summary>The primary purpose study assess central receptor occupancy PF 03654746 H3 receptor single oral dose PF 03654746 .</brief_summary>
	<brief_title>A Phase I , Healthy Volunteer Positron Emission Tomography Study</brief_title>
	<detailed_description>Additional Study Purpose Details : To validate PET ligand use determine receptor occupancy determine receptor occupancy PF-0367456</detailed_description>
	<criteria>Healthy male subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . A BMI low limit 17.5 kg/m2 may round 18.0 kg/m2 ; BMI upper limit 30.5 kg/m2 may round 30.0 kg/m2 acceptable inclusion . An informed consent document sign date subject legally acceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding Screening . History febrile illness within 5 day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen Screening Day 0 . History regular alcohol consumption exceed 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . Positive cotinine screen Screening Day 0 . Treatment investigational drug within 30 day 5 halflives precede first dose study medication ( exclude [ C11 ] PF04621053 ) . 12lead ECG demonstrate QTc &gt; 450 msec Screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue 28 day prior first dose study medication . Chronic ( every day ) use histamine ( H1 , H2 ) inhibitor ( ) within 3 month screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Positron Emission Tomography study healthy volunteer ligand qualification receptor occupancy determination .</keyword>
</DOC>